D-0071-2022 Class III Terminated

Recalled by Ultra Seal Corporation — New Paltz, NY

FDA drug recall D-0071-2022 was initiated by Ultra Seal Corporation on Oct 13, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid. The recall status is terminated (terminated Mar 28, 2022). Affected quantity: 1,367,525 tablets.

Recall details

Product Type
Drugs
Report Date
Nov 3, 2021
Initiation Date
Oct 13, 2021
Termination Date
Mar 28, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,367,525 tablets

Product description

Vica-Cet BACK PAIN RELIEF (Acetaminophen 250 mg/Aspirin 250 mg/Caffeine 65 mg) tablets, 2 tablets/pk, packaged in 10,000 packets, PO# 8967, Mfg. for Tellus/The Provision First Aid Line (Shipping Label)

Reason for recall

Failed Stability Specifications: Out-of-Specification results observed for Aspirin related compound Salicylic Acid.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: AK-9455, exp. date 22-Jan; AK-1109, AK-1110, exp. date 23-Mar; K-9821, exp. date 22-Sep

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0071-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0071-2022. Report a data issue: hello@regdatalab.com.